文献速递结核与非结核分枝杆菌

高剂量利福平、吡嗪酰胺和莫西沙星缩短结核疗程的疗效与肝毒性:老药仍有可为

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究在结核空心纤维系统模型中模拟高剂量方案(莫西沙星800mg/日、利福平1800mg/日、吡嗪酰胺4000mg/日)与标准方案(异烟肼300mg/日、利福平600mg/日、吡嗪酰胺2000mg/日),并加入三维人源肝组织评估肝毒性。高剂量方案杀菌和灭菌效果略优,患者中预计最短疗程缩短(上限3.7个月 vs 4.5-5个月),且乳酸脱氢酶无差异。结论认为高剂量方案可能适度缩短疗程而不增加肝毒性。

要点

  • 高剂量方案灭菌效果杀灭速率0.72 log10 CFU/mL/日,高于标准方案0.56。
  • 患者中预计最短疗程上限:标准方案4.5-5个月,高剂量方案3.7个月。
  • 两方案乳酸脱氢酶浓度各时间点均无差异(P > .05)。

核心结论

  • 与标准方案相比,高剂量方案可能适度缩短结核疗程且不增加肝毒性。

研究设计与样本

  • 在结核空心纤维系统模型中进行杀菌和灭菌效果研究,模拟高剂量方案与标准方案的人体等效剂量。
  • 在胞内结核分枝杆菌空心纤维系统实验中加入三维人源器官型肝脏,基于乳酸脱氢酶评估肝毒性,治疗持续28天。

主要发现

  • 标准方案杀菌效果和灭菌效果实验的杀灭速率分别为0.97(95%CI .91-.99)和0.56(95%CI .49-.59)log10 CFU/mL/日。
  • 高剂量方案杀菌效果和灭菌效果实验的杀灭速率分别为0.99(95%CI .96-.99)和0.72(95%CI .56-.79)log10 CFU/mL/日。
  • 患者中预计灭绝时间上限:标准方案4.5-5个月,高剂量方案3.7个月。
  • 两方案乳酸脱氢酶浓度各时间点均无差异(P > .05)。

临床怎么用

  • 高剂量方案(莫西沙星800mg/日、利福平1800mg/日、吡嗪酰胺4000mg/日)可能作为缩短结核疗程的候选策略,但需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One approach that could increase the efficacy and reduce the duration of antituberculosis therapy is pharmacokinetics/pharmacodynamics-based optimization of doses. However, this could increase toxicity. METHODS: We mimicked the concentration-time profiles achieved by human equivalent doses of moxifloxacin 800 mg/day, rifampin 1800 mg/day, and pyrazinamide 4000 mg/day (high-dose regimen) vs isoniazid 300 mg/day, rifampin 600 mg/day, and pyrazinamide 2000 mg/day (standard therapy) in bactericidal and sterilizing effect studies in the hollow fiber system model of tuberculosis (HFS-TB). In an intracellular Mycobacterium tuberculosis (Mtb) HFS-TB experiment, we added a 3-dimensional human organotypic liver to determine potential hepatotoxicity of the high-dose regimen, based on lactate dehydrogenase (LDH). Treatment lasted 28 days and Mtb bacterial burden was based on colony counts. We calculated the time to extinction (TTE) of the Mtb population in the HFS-TB and used morphism-based transformation and Latin hypercube sampling to identify the minimum therapy duration in patients. RESULTS: The kill rate of standard therapy in the bactericidal effect and sterilizing effect experiments were 0.97 (95% confidence interval [CI], .91-.99) log10 colony-forming units (CFU)/mL/day, and 0.56 (95% CI, .49-.59) log10 CFU/mL/day, respectively. The high-dose regimen's bactericidal and sterilizing effect kill rates were 0.99 (95% CI, .96-.99) log10 CFU/mL/day and 0.72 (95% CI, .56-.79) log10 CFU/mL/day, respectively. The upper confidence bound for TTE in patients was 4.5-5 months for standard therapy vs 3.7 months on the high-dose regimen. There were no differences in LDH concentrations between the 2 regimens at any time point (P > .05). CONCLUSIONS: The high-dose regimen may moderately shorten therapy without increased hepatotoxicity compared to standard therapy.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Srivastava S, Deshpande D, Magombedze G, et al. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! Clin Infect Dis. 2018. PMID: 30496465. doi:10.1093/cid/ciy627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。